G-CSF plus azacitidine versus azacitidine alone for patients with high-risk myelodysplastic syndrome: academic, open label, randomized trial
Trial registration GA trial is registered under EudraCT#: 2013-001639-38.
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Publishing Group
2022-07-01
|
| Series: | Blood Cancer Journal |
| Online Access: | https://doi.org/10.1038/s41408-022-00698-2 |
| _version_ | 1818518379241144320 |
|---|---|
| author | Tomáš Stopka Lubomír Minařík Nina Dusilková Michal Pešta Vojtěch Kulvait Martin Špaček Zuzana Zemanová Marta Kalousová Anna Jonášová |
| author_facet | Tomáš Stopka Lubomír Minařík Nina Dusilková Michal Pešta Vojtěch Kulvait Martin Špaček Zuzana Zemanová Marta Kalousová Anna Jonášová |
| author_sort | Tomáš Stopka |
| collection | DOAJ |
| description | Trial registration GA trial is registered under EudraCT#: 2013-001639-38. |
| first_indexed | 2024-12-11T01:09:37Z |
| format | Article |
| id | doaj.art-4efbf8e16aa74e82b0aac85f039d3f2c |
| institution | Directory Open Access Journal |
| issn | 2044-5385 |
| language | English |
| last_indexed | 2024-12-11T01:09:37Z |
| publishDate | 2022-07-01 |
| publisher | Nature Publishing Group |
| record_format | Article |
| series | Blood Cancer Journal |
| spelling | doaj.art-4efbf8e16aa74e82b0aac85f039d3f2c2022-12-22T01:26:05ZengNature Publishing GroupBlood Cancer Journal2044-53852022-07-011271410.1038/s41408-022-00698-2G-CSF plus azacitidine versus azacitidine alone for patients with high-risk myelodysplastic syndrome: academic, open label, randomized trialTomáš Stopka0Lubomír Minařík1Nina Dusilková2Michal Pešta3Vojtěch Kulvait4Martin Špaček5Zuzana Zemanová6Marta Kalousová7Anna Jonášová8Haematology Clinic, General Faculty HospitalHaematology Clinic, General Faculty HospitalHaematology Clinic, General Faculty HospitalFaculty of Mathematics & Physics, Charles UniversityBIOCEV, 1st Medical Faculty, Charles UniversityHaematology Clinic, General Faculty HospitalCytogenetics, 1st Medical Faculty, General Hospital and Charles UniversityInstitute of Medical Biochemistry and Laboratory Diagnostics, General Faculty HospitalHaematology Clinic, General Faculty HospitalTrial registration GA trial is registered under EudraCT#: 2013-001639-38.https://doi.org/10.1038/s41408-022-00698-2 |
| spellingShingle | Tomáš Stopka Lubomír Minařík Nina Dusilková Michal Pešta Vojtěch Kulvait Martin Špaček Zuzana Zemanová Marta Kalousová Anna Jonášová G-CSF plus azacitidine versus azacitidine alone for patients with high-risk myelodysplastic syndrome: academic, open label, randomized trial Blood Cancer Journal |
| title | G-CSF plus azacitidine versus azacitidine alone for patients with high-risk myelodysplastic syndrome: academic, open label, randomized trial |
| title_full | G-CSF plus azacitidine versus azacitidine alone for patients with high-risk myelodysplastic syndrome: academic, open label, randomized trial |
| title_fullStr | G-CSF plus azacitidine versus azacitidine alone for patients with high-risk myelodysplastic syndrome: academic, open label, randomized trial |
| title_full_unstemmed | G-CSF plus azacitidine versus azacitidine alone for patients with high-risk myelodysplastic syndrome: academic, open label, randomized trial |
| title_short | G-CSF plus azacitidine versus azacitidine alone for patients with high-risk myelodysplastic syndrome: academic, open label, randomized trial |
| title_sort | g csf plus azacitidine versus azacitidine alone for patients with high risk myelodysplastic syndrome academic open label randomized trial |
| url | https://doi.org/10.1038/s41408-022-00698-2 |
| work_keys_str_mv | AT tomasstopka gcsfplusazacitidineversusazacitidinealoneforpatientswithhighriskmyelodysplasticsyndromeacademicopenlabelrandomizedtrial AT lubomirminarik gcsfplusazacitidineversusazacitidinealoneforpatientswithhighriskmyelodysplasticsyndromeacademicopenlabelrandomizedtrial AT ninadusilkova gcsfplusazacitidineversusazacitidinealoneforpatientswithhighriskmyelodysplasticsyndromeacademicopenlabelrandomizedtrial AT michalpesta gcsfplusazacitidineversusazacitidinealoneforpatientswithhighriskmyelodysplasticsyndromeacademicopenlabelrandomizedtrial AT vojtechkulvait gcsfplusazacitidineversusazacitidinealoneforpatientswithhighriskmyelodysplasticsyndromeacademicopenlabelrandomizedtrial AT martinspacek gcsfplusazacitidineversusazacitidinealoneforpatientswithhighriskmyelodysplasticsyndromeacademicopenlabelrandomizedtrial AT zuzanazemanova gcsfplusazacitidineversusazacitidinealoneforpatientswithhighriskmyelodysplasticsyndromeacademicopenlabelrandomizedtrial AT martakalousova gcsfplusazacitidineversusazacitidinealoneforpatientswithhighriskmyelodysplasticsyndromeacademicopenlabelrandomizedtrial AT annajonasova gcsfplusazacitidineversusazacitidinealoneforpatientswithhighriskmyelodysplasticsyndromeacademicopenlabelrandomizedtrial |